NeoGraph Analytics
Medical DevicesNorth America2023 – 2032

Global North America Continuous Glucose Monitoring Market Size, Share and Trends Analysis

North America CGM market valued at US$9.5 Bn in 2023, forecast to US$36.1 Bn by 2032 at 16.0% CAGR.

Revenue, 2023

$9.5B

Forecast, 2032

$36.1B

CAGR, 2024-2032

16%

Report Coverage

North America

Code: north-america-continuous-glucose-monitoring-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The North America continuous glucose monitoring market was US$9.5 Bn in 2023 and is projected to reach US$36.1 Bn by 2032, expanding at a 16.0% CAGR. Growth is driven by rising diabetes prevalence, favorable reimbursement policies, and rapid adoption of wearable and implantable CGM systems. Dexcom and Abbott dominate the competitive landscape, while Medtronic, Senseonics, and Roche strengthen the ecosystem through integrated insulin‑delivery solutions.

02

Key Highlights

1

North America CGM market to exceed US$36 Bn by 2032.

2

Wearable sensors dominate with 60% share, driven by convenience.

3

Dexcom and Abbott together control over 70% of regional revenue.

03

Market Overview

Market Context

North America leads global CGM adoption, fueled by high diabetes prevalence, advanced reimbursement frameworks, and rapid technology upgrades. Wearable devices are most common, while implantable and smartphone‑connected segments are expanding quickly.

North America accounts for roughly 45% of the global CGM market, propelled by high diabetes incidence and advanced healthcare infrastructure. Wearable sensors lead adoption, with implantable and smartphone‑connected devices gaining traction.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Rapid adoption of real‑time CGM in outpatient settingsIntegration of CGM data with digital health platformsExpansion of consumer‑focused CGM (e.g., Abbott Lingo)Increasing reimbursement coverage from major PBMs
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 16%

Base Year (2023)

$9.5B

Forecast (2032)

$36.1B

CAGR (2024-2032)

16%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$9.50B
2024$11.02B
2025$12.78B
2026$14.83B
2027$17.20B
2028$19.95B
2029$23.15B
2030$26.85B
2031$31.14B
2032$36.13B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

Applying a 16.0% CAGR from the 2023 base of US$9.5 Bn yields a US$36.1 Bn market by 2032. Growth will be sustained by sensor innovation, broader payer coverage, and entry of consumer‑focused CGM products.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America45.0%16.5%United States
Europe30.0%14.0%Germany
Asia Pacific25.0%18.0%China

North America

#1
Share: 45.0%CAGR: 16.5%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 14.0%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising diabetes prevalence and obesity rates
  • Improved sensor accuracy and miniaturization
  • Favorable payer reimbursement policies
06

Market Segmentation

By Product Type
Market share distribution across 3 segments
By Product Type — market share by segment, in percent.
SegmentShare
Wearable CGMSkin‑adhered sensors providing real‑time glucose readings.60.0%
Implantable CGMSubcutaneous implants offering continuous 180‑day monitoring.25.0%
Smartphone‑connected CGMDevices that pair directly with mobile apps for data sharing.15.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals
  • Home Care
  • Clinics
07

Regional Analysis

1

North America

Lead: United States
CAGR: 16.5%Share: 45.0%

Largest market due to high adoption, strong reimbursement, and leading OEMs.

2

Europe

Lead: Germany
CAGR: 14.0%Share: 30.0%

Growing demand driven by EU MDR compliance and expanding diabetes programs.

3

Asia Pacific

Lead: China
CAGR: 18.0%Share: 25.0%

Fastest growth region owing to rising diabetic population and digital health investments.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
68.0%
+16.2%
Germany
10.0%
+13.5%
China
7.0%
+19.0%
08

Competitive Landscape

D

Dexcom

United States

Leader5.2B

Dominates with G7 and G6 systems; ~35‑40% global revenue share and broad PBM coverage.

Leading CGM innovator with real‑time continuous monitoring platforms.

A

Abbott Laboratories

United States

Challenger4.8B

Strong with FreeStyle Libre franchise; targeting US$10 Bn Libre sales by 2028.

Major diagnostics firm offering the FreeStyle Libre flash‑monitoring system.

M

Medtronic

Ireland

Follower3.1B

Integrated pump‑CGM solutions; MiniMed 780G and Simplera Sync sensor.

Integrated insulin‑pump and CGM provider for diabetes management.

09

Recent Developments

25
2025Dexcom

Launched G7 with enhanced accuracy and Bluetooth connectivity

24
2024Abbott

Introduced consumer CGM brand Lingo for wellness market

10

Regulatory Landscape

U.S. FDA 510(k) clearance pathwayEU Medical Device Regulation (MDR) 2017/745
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

Target Dexcom and Abbott for stable growth; watch Medtronic's integrated pump‑CGM synergy.

Operators

Prioritize wearable CGM integration with digital health platforms to capture expanding home‑care segment.

Payers

Expanding CGM reimbursement can reduce long‑term diabetes complications and costs.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.